Spring Bank Pharmaceuticals Inc. ($SBPH) announced top line results from a Phase 2a clinical trial, ACHIEVE, assessing its SB 9200 for the treatment of chronic hepatitis B virus (HBV) infection. The study showed no serious adverse events during the 12-week study. Thus, the results showed an encouraging safety profile.
Veracyte ($VCYT) announced that the clinical validation studies of its Envisia Genomic Classifier in enhancing the diagnosis of idiopathic pulmonary fibrosis showed positive results including its ability to detect usual interstitial pneumonia (UIP), a pattern whose presence is necessary for the diagnosis of IPF. The results were generated from a 30-site study, BRAVE, involving 236 transbronchial biopsy samples from 49 patients.